SEC-FDA agreement heightens focus on life science disclosure and governance risks

Key takeaways:

  • A memorandum of understanding between the SEC and FDA expands information sharing, potentially making inconsistencies between regulatory communications and investor disclosures easier to identify.

  • Enhanced regulatory visibility may increase underwriting scrutiny of life sciences companies that already face significant securities litigation exposure.

  • Life sciences companies should strengthen disclosure and insider trading controls, improve information governance, and reassess D&O limits and investigation coverage.

Life sciences companies have long faced significant regulatory and securities litigation risks. Their valuations can fluctuate significantly in response to clinical trial outcomes and regulatory feedback and approvals from the Food and Drug Administration (FDA).

While the agreement does not create new disclosure obligations, it may provide regulators with greater visibility into information that could affect investors. For life sciences companies and their senior leaders, this reinforces the importance of strong governance, disclosure controls, and directors and officers liability (D&O) insurance.

Closer connections between the SEC and FDA

Although the SEC and FDA have distinct regulatory missions, the two agencies have long cooperated on matters involving FDA-regulated companies. A memorandum of understanding (MOU) signed in August formalizes and expands that relationship (opens a new window), establishing a framework for the agencies to share nonpublic information in both directions. The agreement also establishes designated points of contact and calls for standardized procedures for requesting and transmitting information.

The MOU does not create new disclosure requirements, but could make it easier for the SEC compare public disclosures concerning FDA reviews, clinical trials, product approvals, and other regulatory developments against information available through the FDA. Information developed through SEC inquiries and investigations could likewise reach the FDA, subject to applicable legal and confidentiality requirements.

SEC enforcement activity has fallen substantially (opens a new window) under the second Trump administration. While enforcement and examination priorities continue to evolve, the MOU suggests that life sciences companies are likely to remain an area of regulatory interest given the industry's reliance on market-sensitive regulatory developments.

The creation of a formal information-sharing framework at a time when the SEC is operating with fewer resources could help the agency more readily identify discrepancies between what companies tell the Street and what they communicate to the FDA.

As law firm Freshfields recently noted, information relevant to regulatory actions and litigation against life sciences companies often emerges gradually (opens a new window). Clinical trial data, FDA feedback, manufacturing issues, and other developments can change expectations about a product well before the FDA makes any final decision.

These developments can also immediately affect valuations, with significant stock price declines triggering shareholder litigation. Life sciences companies must therefore balance investors’ demands for timely information against the risk of communicating interpretations of FDA interactions before the regulatory picture comes into focus.

Greater information sharing could give the SEC a clearer view into that process. Information from the FDA could make it easier to compare companies’ public characterizations of regulatory developments with the underlying regulatory record. Areas that could receive greater scrutiny include disclosures related to:

  • Serious adverse event trends, including undisclosed or insufficiently disclosed safety signals.

  • FDA concerns about trial design or patient safety.

  • Clinical holds or other restrictions affecting trial progress.

  • Requests for additional data, analyses, or studies affecting timelines or the likelihood of approval.

  • Disagreements with the FDA over trial endpoints.

Discrepancies in these and other areas could create potential avenues for regulatory investigations and, in some cases, securities and derivative litigation. Life sciences companies faced 60 securities class-action filings in 2025 (opens a new window), according to law firm Goodwin, up 15% from 2024 even as filings across all industries fell 8%. Although courts dismissed or substantially narrowed most life sciences litigation in 2025, it remains the largest industry target for securities class-action suits, Goodwin found.

Revisiting disclosure, governance, and D&O insurance

The MOU is unlikely to fundamentally alter underwriting approaches for life sciences risks. However, it reinforces the importance of governance, disclosure controls, and escalation procedures. Underwriters may focus on how information flows between and among senior management and regulatory, legal, compliance, and investor relations functions, including how significant FDA developments are identified, escalated, and communicated to investors.

Life sciences risk professionals and senior executives should be prepared to explain these processes in D&O underwriting presentations. A clear account can help underwriters better understand a company’s approach to managing its risk.

Traditional public company D&O policies generally provide broader protection for investigations involving insured individuals than for investigations of the corporate entity itself. Buyers should understand how their policies would respond if regulatory scrutiny develops into informal or formal investigations.

For life sciences companies, the MOU underscores the importance of following established best practices. That applies to public companies as well as those preparing to go public, which should ensure that disclosures regarding FDA interactions and regulatory milestones align with underlying regulatory records.

Specifically, organizations, in consultation with in-house and outside counsel, should focus on:

  • Maintaining strong disclosure controls. Public disclosures and, for companies preparing to go public, offering and other investor facing materials concerning FDA meetings, clinical developments, review timelines, product approvals, and other regulatory matters should be accurate, complete, and consistent with the underlying regulatory record. Particular care may be warranted when facts or potential outcomes are still evolving.

  • Strengthening information governance. Companies should have appropriate processes for sharing and escalating information among regulatory, legal, compliance, senior management, and investor relations functions. These processes should account for both what is communicated to regulators and what is ultimately communicated to investors and to the public.

  • Reviewing insider trading controls. Clinical and regulatory information can emerge well before a final FDA decision, potentially giving insiders information that has not yet reached investors. With significant company valuations and, in some cases, employee compensation tied to the outcomes of regulatory developments, companies should ensure that insider trading policies and controls appropriately address periods surrounding significant FDA interactions and clinical developments.

  • Reassessing D&O protection. Working with their brokers and advisors, life sciences companies should evaluate whether current limits, retentions, and program structures remain appropriate for their risk profiles. This review should include consideration of Side A protection and the availability, scope, and triggering requirements of regulatory and entity investigation coverage, which can vary significantly among policies.

Importantly, if entity investigation coverage is purchased, not every interaction with the SEC or FDA may be covered. Policy wording and the circumstances of an inquiry will control the outcome. It is important that life sciences companies — with support from experienced brokers — understand this commonly misunderstood coverage before regulatory scrutiny arises.

For more information: